- Home
- SUUN vs CTOR Comparison
SUUN vs CTOR Comparison
Compare SUUN & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUUN
- CTOR
- Stock Information
- Founded
- SUUN 2013
- CTOR 2021
- Country
- SUUN Canada
- CTOR United States
- Employees
- SUUN N/A
- CTOR N/A
- Industry
- SUUN
- CTOR
- Sector
- SUUN
- CTOR
- Exchange
- SUUN Nasdaq
- CTOR NYSE
- Market Cap
- SUUN 75.1M
- CTOR 63.7M
- IPO Year
- SUUN N/A
- CTOR N/A
- Fundamental
- Price
- SUUN $1.47
- CTOR $5.30
- Analyst Decision
- SUUN Strong Buy
- CTOR Buy
- Analyst Count
- SUUN 1
- CTOR 2
- Target Price
- SUUN $6.00
- CTOR $6.00
- AVG Volume (30 Days)
- SUUN 464.2K
- CTOR 3.3M
- Earning Date
- SUUN 08-14-2025
- CTOR 08-11-2025
- Dividend Yield
- SUUN N/A
- CTOR N/A
- EPS Growth
- SUUN N/A
- CTOR N/A
- EPS
- SUUN N/A
- CTOR N/A
- Revenue
- SUUN $25,798,969.00
- CTOR N/A
- Revenue This Year
- SUUN $15.42
- CTOR N/A
- Revenue Next Year
- SUUN $62.53
- CTOR N/A
- P/E Ratio
- SUUN N/A
- CTOR N/A
- Revenue Growth
- SUUN N/A
- CTOR N/A
- 52 Week Low
- SUUN $1.23
- CTOR $0.55
- 52 Week High
- SUUN $6.43
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- SUUN 38.90
- CTOR N/A
- Support Level
- SUUN $1.46
- CTOR N/A
- Resistance Level
- SUUN $1.64
- CTOR N/A
- Average True Range (ATR)
- SUUN 0.14
- CTOR 0.00
- MACD
- SUUN -0.00
- CTOR 0.00
- Stochastic Oscillator
- SUUN 16.90
- CTOR 0.00
About SUUN SolarBank Corporation Common Stock
SolarBank Corp is an independent renewable and clean energy project developer and asset operator based in Canada and the United States. It is engaged in the development and operation of solar photovoltaic power generation projects in the province of Ontario and the state of New York. The company operates in two principal geographical areas - Canada and United States with a substantial portion of its overall revenue being generated from United States.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.